<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313286</url>
  </required_header>
  <id_info>
    <org_study_id>14233</org_study_id>
    <secondary_id>I3P-FW-GKBG</secondary_id>
    <nct_id>NCT01313286</nct_id>
  </id_info>
  <brief_title>A Study to Compare Two Forms of LY2608204 in Healthy People</brief_title>
  <official_title>The Relative Bioavailability of a Proposed Phase 2 LY2608204 Test Formulation Compared With the Current Phase 1 LY2608204 Reference Formulation After Administration of a Single Oral 80-mg Dose in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare 2 formulations of the study drug (LY2608204) in terms
      of how much gets into the blood stream and how long it takes the body to get rid of it.
      Information about any side effects that may occur will also be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of LY2608204 Test Formulation to LY2608204 Reference Formulation, area under the concentration time curve (AUC)</measure>
    <time_frame>For up to 168 hours after each administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of LY2608204 Test Formulation to LY2608204 Reference Formulation, maximum concentration (Cmax)</measure>
    <time_frame>For up to 168 hours after each administration of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2608204 Reference, LY2608204 Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2608204 Test, LY2608204 Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2608204 Reference</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2608204 Reference, LY2608204 Test</arm_group_label>
    <arm_group_label>LY2608204 Test, LY2608204 Reference</arm_group_label>
    <other_name>Glucokinase Activator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2608204 Test</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2608204 Reference, LY2608204 Test</arm_group_label>
    <arm_group_label>LY2608204 Test, LY2608204 Reference</arm_group_label>
    <other_name>Glucokinase Activator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a healthy male or a female who cannot become pregnant

          -  Must have body mass index (BMI) of 18.5 to 32 kg/mÂ², inclusive

          -  Blood pressure as well as blood and urine laboratory test results must be acceptable
             for the study

          -  The veins must be suitable for easy blood collection

          -  Must be willing to be available for the whole study and be willing to follow study
             procedures

          -  Must have given written informed consent

        Exclusion Criteria:

          -  Were in another new drug or medical research study in the last 30 days

          -  Have participated in this study or any other study with LY2608204 before

          -  Have taken drugs similar to LY2608204 (glucokinase activators) before and was found to
             be allergic to the drug

          -  Have drug allergy to more than 3 types of medications given by injection

          -  Currently have or used to have health problems or laboratory test results that in the
             opinion of the doctor, could interfere with understanding the results of this study

          -  Electrocardiogram (ECG) readings are not suitable for the study

          -  Are infected with hepatitis B

          -  Are infected with human immunodeficiency disease virus (HIV)

          -  Are using or intend to use over-the-counter medication or prescription medications
             within 14 days, from the start of the first study dosing until end of study

          -  Are unwilling to follow dietary restrictions/requirements for the study including (i)
             refrain from consuming foods or beverages containing grapefruit pomelo, star fruit, or
             Seville orange within 14 days of the start of the study drug dosing until collection
             of the last blood sample for drug assay; (ii) consume only the meals provided during
             dosing day at the clinical research unit (CRU)

          -  Have a regular alcohol intake greater than 21 units per week (males) and 14 units per
             week (females) or are not willing to abstain from alcohol while in the research unit

          -  Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while
             at the clinic

          -  Have a history of drug or alcohol abuse

          -  Have donated 450 mL or more of blood in the last 3 months (this is about the same as
             the usual volume given in a blood donation)

          -  The study doctor thinks the subject should not participate for any other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <pending_results>
    <submitted>February 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

